NASDAQ:RNA

Avidity Biosciences Stock Predictions

Healthcare > Biotechnology

Buy RNA

*Your capital is at risk

$12.22

-0.240 (-1.93%)

At Close: Jul 13, 2026

Currently predicting for Tue, 14 Jul 2026

RNA Live board

Community Bull/Bear

Target Next close

Join the RNA prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

RNA Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For RNA

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

RNA Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT AVIDITY BIOSCIENCES LLC

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to tr...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
SRPT $17.02	10.58%	Jun 29
NMRK $15.02	0.466%	Jun 24
X XMAX $8.34	2.40%	Jun 24
NESR $25.07	12.49%	Jun 23
CAG $13.43	6.70%	Jun 23

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by